DexCom (DXCM +3.4%) gets a boost after Wunderlich initiates coverage with a Buy, saying that growing visibility on the company's Gen4 approval process should push the stock near, or possibly through its $12 price target over the next 12 months.
DexCom (DXCM +3.4%) gets a boost after Wunderlich initiates coverage with a Buy, saying that...
From other sites
Video at CNBC.com (Oct 15, 2015)
Video at CNBC.com (Aug 13, 2015)
at CNBC.com (Jan 15, 2015)
at CNBC.com (Sep 4, 2014)
at CNBC.com (Aug 25, 2014)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs